Oncology

EHA 2026 late-breaking data featured phase 3 trials in CLL, AML, multiple myeloma, and myelofibrosis, plus early CAR T data in B-cell lymphoma and ITP.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

Organized screening in Hong Kong narrowed socioeconomic disparities over 9 years, although suboptimal uptake persists in key groups.

Ziftomenib plus intensive chemotherapy produced high response and MRD negativity rates with manageable safety in newly diagnosed AML.

Long-term LUNA3 data showed rilzabrutinib delivered durable platelet responses, reduced bleeding and fatigue, and maintained safety in ITP.

On paper, the OCM cost Medicare millions. A decade later, physicians say its lessons are priceless.

In patients with NSCLC, 3+1 lymph node sampling was not linked to higher postoperative complications, supporting guideline adherence.

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

FDA decisions in May 2026 included 5 major oncology approvals, including first-in-class therapies for breast cancer, AML, MCL, and NMIBC.

Men and urban minority patients with early-onset CRC face elevated CVD death risk, highlighting gaps in survivorship care and research, Meng-Han Tsai, PhD, said.

Structural racism was associated with wider NSCLC survival disparities, with a 10-point Black-White gap in highly segregated counties.

Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address.

An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.

Trauma after cancer is underdiagnosed and often persists into survivorship, with experts urging trauma-informed screening in oncology care.

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

Early-onset CRC CVD mortality disparities highlight the need for integrated data and risk-based survivorship care, said Meng-Han Tsai, PhD.

An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease.

ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH.

Updated toxicity criteria improve immunotherapy toxicity management in melanoma, spotlighting rapid action for rare cardiotoxicity, says Igor Puzanov, MD, MSCI, FACP.

According to the ROADS trial, GammaTile cesium-131 brachytherapy boosts local control and survival in brain cancer treatment, matching SRT safety while avoiding radiation delays.

Early palliative care integration in oncology boosts symptom alleviation and quality of life, but access, workforce shortages, and institutional barriers slow referrals.